DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)

Trial Details

NCT ID
NCT06176261
Phase
PHASE2
Sponsor
Sarah Sammons, MD
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Datopotamab Deruxtecan
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • Metastatic breast cancer that is pathologically confirmed to be HER2-negative according to 2018 ASCO/CAP guidelines 55.
  • Radiological confirmation of metastatic disease.
  • Cohorts A and B: Presence of newly diagnosed brain metastases or brain metastases progressing after prior local and/or systemic therapy.
  • Cohorts A and B: Participants must have a baseline MRI of the brain performed with and without gadolinium contrast, and must have central nervous s…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →